{ "article": { "format_version": 5, "presentation": "complete-card", "overview": "Menopause names the end of menstrual periods; perimenopause is the surrounding transition. Changing cycles, hot flashes, broken sleep and bone-health questions can overlap, but they need different answers. The calendar helps describe the stage, symptom interference helps guide treatment, and age and history help guide bone assessment. Hormone therapy and several nonhormone treatments can relieve bothersome hot flashes. A useful next step is to bring your pattern and your main concern to a qualified clinician.", "sections": [ { "id": "understanding-the-transition", "role": "explanation", "title": "What changes around the last period", "intro": "The stage name describes ovarian aging. It does not tell you how much help you need or when symptoms will end.", "items": [ { "label": "Understand menopause as a life stage with a changing hormone pattern", "text": "Menopause is the point at which periods have permanently ended because the ovaries have lost their usual follicular function. A follicle is the small structure in an ovary that contains a developing egg. During perimenopause, the years around that point, ovarian activity becomes less predictable; estrogen can fluctuate before settling at a lower level. This helps explain why changing cycles, sudden heat and disrupted nights can occur together. WHO describes substantial variation: some women have few symptoms, while others have symptoms that interfere with daily life. A normal life stage can still deserve treatment. Its significance is how it affects you, rather than whether you match someone else's symptom list. Mayo Clinic gives a U.S. average menopause age of 51, while estimates differ slightly across sources; an average age is not a personal deadline.", "source_ids": [ "who-menopause", "endo-menopause", "mayo-menopause" ] }, { "label": "Use the calendar to describe the stage, with room for exceptions", "text": "For natural menopause, the usual marker is twelve consecutive months without a period when another cause does not explain the absence. It is retrospective: you recognize the final menstrual period after time has passed. Siobán Harlow and the STRAW+10 workshop use persistent differences of at least seven days between consecutive cycle lengths to mark early transition, and a gap of at least sixty days to mark late transition. That late stage commonly lasts one to three years; their definition of perimenopause extends through the first twelve months after the final period. The workshop intended a common framework across age, ethnicity, body size and lifestyle, while recognizing situations where bleeding criteria are harder to use. These are staging clues, not instructions to diagnose yourself. Hormonal contraception can mask bleeding. A hysterectomy removes the uterus, so the period calendar is lost even if the ovaries remain; removal of both ovaries is a different event. A clinician interprets symptoms, surgery and medication history together.", "source_ids": [ "straw-2012", "cms-stages" ] }, { "label": "Let a clinical history answer the routine midlife testing question", "text": "FSH, or follicle-stimulating hormone, is a signal involved in ovarian function. Its level can fluctuate during the transition, making one measurement a poor summary of the preceding months. NICE recommends identifying typical perimenopause or menopause clinically in otherwise healthy people aged 45 or over with relevant symptoms, rather than routinely ordering hormone or ovarian-reserve tests. That recommendation does not mean every test is useless or every new symptom is menopause. Younger age, an unusual presentation or medication-masked cycles can change the assessment. The practical preparation is a history of bleeding, symptoms and medicines. Ask what question a proposed blood test would answer before treating its number as the final verdict.", "source_ids": [ "nice-ng23", "endo-menopause" ] }, { "label": "Seek assessment when periods stop before 45", "text": "Periods stopping unusually early need assessment rather than a wait for the ordinary twelve-month anniversary. The international ovarian-insufficiency guideline distinguishes premature ovarian insufficiency, or POI, before age 40 from early menopause at ages 40–44. POI means loss of normal ovarian activity, but nonsurgical POI can include intermittent activity and a chance of natural conception. It is not synonymous with an absolute infertility verdict. The care discussion includes causes, symptoms, bone and cardiovascular health, and fertility goals. Hormone treatment may address health needs until the usual menopause age even without troublesome heat, subject to the person's history. That differs from starting hormones much later for disease prevention. The guideline also acknowledges limited evidence for many POI-specific choices; an individualized assessment remains essential.", "source_ids": [ "poi-guideline", "cms-stages" ] } ] }, { "id": "recognize-your-main-question", "role": "application", "title": "Which part is disrupting your life?", "intro": "These four situations help identify the question to bring to care. Several can be true at once.", "items": [ { "label": "Describe changing periods before trying to name the final one", "text": "You might be thinking, 'My periods are farther apart, but they still come—am I in menopause?' The answer is that changing cycles can fit perimenopause before menopause can be confirmed retrospectively. The Canadian Menopause Society describes the distinction through both bleeding patterns and symptoms, while NICE emphasizes the clinical story in typical midlife presentations. Write down when bleeding occurred, how it changed and whether you use hormonal medicines. Include surgery history if it applies. A symptom diary is a communication aid, not an obligation to collect a perfect year of data before asking for help. Very heavy, unusually frequent or new postmenopausal bleeding belongs in an assessment rather than being assumed to be another stage marker.\n\nImagine someone brings a note saying 'probably menopause' but no description of what changed. A more useful account separates changing cycle dates, interrupted sleep and how symptoms affect daily life, alongside relevant medicines or surgery. Those details give the clinician questions to assess instead of a label to accept. A missing date can be marked uncertain; it need not delay seeking help.\n\nIf a symptom improves while another persists, that is worth describing separately at follow-up. It does not mean the whole experience must have one cause or one treatment. This invented visit preparation illustrates the difference between describing a stage and investigating a symptom. It does not determine menopause from a diary, prescribe a test, or make unexpected bleeding something to watch indefinitely rather than bring to clinical attention.", "source_ids": [ "cms-stages", "nice-ng23", "nhs-heavy-bleeding" ] }, { "label": "Describe what heat interrupts, as well as how often it happens", "text": "You might be thinking, 'The heat is still interrupting meetings years later—shouldn't it be over?' A vasomotor symptom is a hot flash or night sweat: a sudden heat episode, often with flushing and sweating. The Menopause Society explains that episodes differ greatly in frequency and severity. For a visit, 'I lose my train of thought twice during most meetings' or 'I change bedding at night' can be as useful as a rough episode count. Those details describe interference, which is a meaningful treatment outcome. They help distinguish a tolerable symptom from a symptom worth treating. A new or unusual pattern of sweating still deserves clinical consideration; the word menopause should not explain away every possible cause.", "source_ids": [ "society-hot-flashes", "avis-duration" ] }, { "label": "Describe the whole night when sleep remains difficult", "text": "You might be thinking, 'I have time to sleep, but I keep waking and cannot get back to sleep.' Night sweats can be one cause of waking, while an insomnia pattern can persist alongside them. Hadine Joffe studies these overlapping problems, and Susan McCurry's trial tested structured insomnia care in women who also had hot flashes. Tell the clinician whether heat woke you, whether you were already awake, how long returning to sleep took and what happens during the day. Also mention loud snoring, gasping or witnessed breathing pauses. The National Heart, Lung, and Blood Institute identifies these as reasons to consider sleep apnea, which requires its own assessment. A wearable's reassuring sleep score does not replace that history.", "source_ids": [ "mccurry-cbti", "p-joffe", "nhlbi-apnea" ] }, { "label": "Ask about bone health and strength even without pain", "text": "You might be thinking, 'I feel fine, but do I need to change my lifting or get a bone scan?' Bone loss often gives no useful day-to-day warning before a fracture. USPSTF screening guidance uses age and fracture-risk factors rather than whether someone feels strong. Wendy Kohrt's work also distinguishes changes in muscle and body composition from symptoms such as hot flashes. Mention previous fractures, falls, medicines that affect bone and the activity you currently do. A bone-density discussion and a supervised exercise discussion serve different purposes: one helps assess risk, the other helps choose suitable loading. Neither assumes that every person needs a scan immediately or should begin heavy lifting from a generic page.", "source_ids": [ "uspstf-bone", "p-kohrt", "liftmor-2018" ] } ] }, { "id": "heat-duration-and-meaning", "role": "findings", "title": "What hot-flash research actually measured", "intro": "Averages are useful for expectations. They cannot supply your personal stop date.", "items": [ { "label": "Allow for a course measured in years", "text": "Crandall and colleagues' clinical review estimates that roughly 50%–75% of women have vasomotor symptoms during the transition. Nancy Avis and colleagues analyzed 1,449 women with frequent hot flashes or night sweats in the Study of Women's Health Across the Nation, or SWAN. Frequent meant symptoms on at least six days in the preceding two weeks. The median total duration was 7.4 years; among 881 women whose final period was observed, symptoms persisted a median of 4.5 years after it. A median is the middle of the observed distribution, not a treatment deadline. Women reporting frequent symptoms before or early in the transition tended to have longer courses, and African American women had the longest median among the groups studied. These observations correct the idea of a universal one- or two-year limit. They do not predict one person's duration or establish an inherent biological explanation for every group difference.", "source_ids": [ "avis-duration", "crandall-review" ] }, { "label": "Measure relief in the outcome that matters to you", "text": "A therapy can reduce episode frequency, lessen severity, improve sleep or make heat less disruptive without doing all four equally. Myra Hunter's MENOS studies illustrate the distinction. King's College London's report describes two randomized trials: one in 96 women after breast-cancer treatment, and another in 140 otherwise healthy women with troublesome menopause symptoms. Group or guided self-help cognitive behavioral therapy improved how problematic participants rated hot flashes and night sweats, with benefits sustained through 26 weeks. The method helps with interpretations and responses to episodes; it does not imply that heat is imaginary. Research on flash counts and research on coping answer different questions. When reviewing a treatment, ask which outcome improved, compared with what, and in which group.", "source_ids": [ "menos-trials", "p-hunter" ] } ] }, { "id": "options-for-bothersome-heat", "role": "findings", "title": "Which treatments have evidence for heat?", "intro": "Treatment choice depends on your goals, medical history, preferences, availability and the particular product.", "items": [ { "label": "Consider hormone therapy for troublesome symptoms", "text": "Systemic hormone therapy circulates through the body, commonly using estrogen with an additional protective medicine when needed. Carolyn Crandall, Jyothi Mehta and JoAnn Manson's 2023 clinical review describes systemic estrogen as reducing vasomotor-symptom frequency by roughly 75% on average in the reviewed research. A review estimate is not a promised result for one person. The Menopause Society's 2022 statement calls hormone therapy the most effective vasomotor treatment and records benefits for bone loss and fracture. It describes a generally favorable benefit-risk balance for appropriately selected symptomatic women younger than 60 or within ten years of menopause onset, without contraindications. That supports an informed option rather than a universal requirement. The reasons to consider it, and the reasons it may not suit you, belong in the same discussion.", "source_ids": [ "crandall-review", "society-ht-2022" ] }, { "label": "Ask which nonhormone option matches your goal and history", "text": "Nonhormone does not mean untested, and it does not mean free of side effects. Chrisandra Shufelt's 2023 Menopause Society panel recommended menopause-specific CBT, clinical hypnosis, selected SSRI/SNRI medicines, gabapentin and fezolinetant on its strongest evidence tier. SSRI and SNRI describe medicine classes that affect brain signaling; some are used for hot flashes as well as other conditions. The panel gave different evidence ratings to oxybutynin, weight loss and stellate ganglion block, an injection near nerves in the neck. Those options are not interchangeable, and the injection is a specialist procedure. A 2023 list also predates later approvals and safety changes. A prescriber can explain indication, interactions, monitoring and expected benefit for the option being considered; this is not a menu to combine yourself.", "source_ids": [ "society-nonhormone-2023", "society-nonhormone-handout", "p-shufelt" ] }, { "label": "Review safety requirements for medicines that target hot flashes", "text": "Fezolinetant, sold as VEOZAH, blocks a neurokinin-3 receptor involved in temperature regulation rather than supplying estrogen. The FDA added a boxed warning for rare serious liver injury in December 2024. Its safety communication describes liver bloodwork before treatment, monthly for the first three months, then at months six and nine, and instructions to stop the medicine and seek medical attention if liver-injury symptoms develop. Yellow skin or eyes, dark urine or new abdominal pain are examples to discuss promptly. Elinzanetant, sold as LYNKUET, blocks neurokinin-1 and -3 receptors; the FDA approved it on October 24, 2025 for moderate-to-severe menopausal heat. Its approval label also requires liver assessment and warns about drowsiness, daytime impairment, interactions and pregnancy. 'Nonhormonal' describes mechanism, not a safety guarantee.", "source_ids": [ "fda-veozah-safety", "fda-veozah-label", "fda-lynkuet-snapshot", "fda-lynkuet-label" ] }, { "label": "Read a new approval through the comparison it tested", "text": "The FDA's LYNKUET snapshot describes two main efficacy trials in postmenopausal women with at least fifty moderate-to-severe hot flashes per week. At twelve weeks, the drug groups averaged about 3.2 fewer daily episodes than placebo after adjustment for baseline and trial factors. Both drug and placebo groups improved, so the extra difference is more informative than the drug group's change alone. The trials were not a head-to-head comparison with hormone therapy or fezolinetant. The FDA's tables describe participants aged 40–65, leaving older adults outside that reported age range; some racial groups had too few participants for confident subgroup conclusions. Approval establishes a tested option for a defined use. It does not establish that this is the best treatment for every stage, age or medical history.", "source_ids": [ "fda-lynkuet-snapshot" ] } ] }, { "id": "weigh-hormone-decisions", "role": "perspectives", "title": "Why hormone advice can sound contradictory", "intro": "Timing, formulation, route and duration are genuine decision questions. They should stay distinct from public slogans about mandatory treatment or a lifetime ban.", "items": [ { "label": "Read the WHI answer with the regimen and prevention question attached", "text": "The Women's Health Initiative's 2002 combined-hormone trial enrolled 16,608 postmenopausal women aged 50–79, with a mean age around 63. It compared a daily oral regimen of conjugated equine estrogen, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, with placebo. The trial stopped after an average 5.2 years because the overall prevention balance favored harm: more coronary events, stroke, pulmonary embolism and invasive breast cancer, alongside fewer hip fractures and colorectal cancers. All-cause mortality was not affected during that trial. Those findings matter. They are not a trial of every modern hormone product or of every younger person seeking symptom relief. JoAnn Manson's 2024 review preserves the conclusion against using hormones for broad chronic-disease prevention while allowing treatment for bothersome heat in suitable early-menopause candidates.", "source_ids": [ "whi-2002", "whi-review-2024" ] }, { "label": "Compare absolute risk as well as relative risk", "text": "A relative risk describes a proportional difference; absolute risk describes how many people experience an event. The same proportional increase can produce more additional events in an older group with a higher starting risk. Manson's thirteen-year WHI overview found lower absolute adverse-event rates in younger participants than in older participants, with important differences between regimens. The age analyses refine the conversation; they are not a separate trial proving that every modern regimen prevents disease when started early. The original combined trial reported about eight additional invasive breast cancers per 10,000 person-years with its regimen. That figure belongs to its population and follow-up, rather than becoming your own annual risk. Ask for the baseline risk, the additional events and the time horizon relevant to the proposed product.", "source_ids": [ "whi-followup-2013", "whi-2002" ] }, { "label": "Keep estrogen-alone and combined-therapy findings separate", "text": "WHI assigned women with a uterus to the combined estrogen/progestin trial and women with a prior hysterectomy to the estrogen-alone trial. Manson's 2013 cumulative analysis found higher invasive breast-cancer incidence with the combined regimen and lower incidence with the studied estrogen-alone regimen than with placebo. These are different trial populations and treatments, not permission to use estrogen alone when the uterus is present. Systemic estrogen can stimulate the endometrium, the uterine lining, so appropriate endometrial protection is needed, usually with a progestogen. A progestogen is a medicine with progesterone-like protective effects. The breast findings do not settle uterine safety. In a visit, identify the actual regimen and why its components are needed before comparing headline claims about 'hormones.'", "source_ids": [ "whi-followup-2013", "society-ht-handout", "society-ht-patient" ] }, { "label": "Discuss route as a risk detail, with honest uncertainty", "text": "Transdermal estrogen enters through the skin, such as from a patch or gel; oral estrogen is swallowed. The Menopause Society notes evidence suggesting lower clot risk with transdermal treatment, while also explaining the lack of large randomized head-to-head trials for major clinical outcomes. A possible comparative advantage is not proof that patches eliminate stroke, clot or breast-cancer risk. Prior clots, stroke, heart disease, liver disease, unexplained bleeding and estrogen-sensitive cancers can change whether systemic therapy is appropriate at all. Mention vascular history, migraine history, medicines and surgery at the start of the consultation. A patch is still a prescription treatment, and changing route yourself bypasses the assessment that makes the comparison useful.", "source_ids": [ "society-ht-2022", "society-ht-patient", "p-shufelt" ] }, { "label": "Review duration through a continuing reason for treatment", "text": "Some advice proposes a fixed stopping anniversary; other advice treats continued use as automatic. The Menopause Society instead ties longer use to documented indications, such as persistent vasomotor symptoms, with shared decisions and periodic reassessment. That leaves legitimate uncertainty about the best duration for different people and products. It does not make five years on treatment a universal stop rule or promise that indefinite treatment is risk-free. NICE recommends an initial treatment review at three months and subsequent annual review, with earlier review when symptoms, side effects or other concerns warrant it. Revisit the benefit you actually notice, new health conditions, the product and dose, and the reason to continue. A follow-up is part of care, not evidence that the first decision failed.", "source_ids": [ "society-ht-2022", "nice-ng23", "p-christmas" ] }, { "label": "Interpret a changed warning label without erasing individual risk", "text": "On February 12, 2026 the FDA announced approved labeling changes for an initial six menopausal hormone products, removing cardiovascular, breast-cancer and probable-dementia risk statements from their boxed warnings. This is a regulatory labeling change affecting specified products; it is not proof that all formulations have become risk-free or that the same label change applies to every product. Clinical evidence, the rest of the product label and your own contraindications still matter. The distinction also helps resolve apparent conflicts between an older leaflet and a newer announcement. Ask the prescriber or pharmacist to review the current label for the exact medicine. A warning's position on the label does not by itself establish a new indication for lifelong disease prevention.", "source_ids": [ "fda-ht-labels-2026", "whi-review-2024" ] } ] }, { "id": "repair-the-night", "role": "findings", "title": "What helps when nights stay broken?", "intro": "Night sweats and insomnia can overlap. A useful assessment does not require one to explain the other completely.", "items": [ { "label": "Use the insomnia trial to understand what structured care can change", "text": "Susan McCurry and colleagues randomized 106 peri- or postmenopausal women aged 40–65 with insomnia and at least two daily hot flashes to six telephone CBT-I sessions or menopause education. CBT-I means cognitive behavioral therapy for insomnia: structured work on sleep timing, time in bed, habits and thoughts that sustain insomnia. After eight weeks, insomnia-severity scores fell by 9.9 points with CBT-I versus 4.7 with education; group differences remained at 24 weeks. Hot-flash counts did not differ, although interference improved. Better sleep did not require every heat episode to disappear. This was one selected, largely White study population, not a trial of every app or a proof that casual bedtime tips are equivalent. Ask about access to structured insomnia care rather than trying to recreate the trial's sleep restrictions alone.", "source_ids": [ "mccurry-cbti", "p-mccurry" ] }, { "label": "Keep breathing, mood and daytime function in the assessment", "text": "Repeated breathing pauses or gasping, loud snoring and unintended daytime sleepiness point toward a different sleep question from difficulty falling back asleep. NHLBI explains that sleep apnea can present with insomnia or fatigue in women as well as more familiar snoring symptoms. Depression, anxiety, medicines and other conditions can also belong in a clinical sleep history. Pauline Maki's menopause research examines mood and cognition, while Joffe's work connects midlife sleep and vasomotor symptoms. Those research connections support asking about the whole pattern; they do not diagnose the cause of your tiredness or a memory lapse. When heat treatment helps but sleep remains poor, the remaining problem is worth assessing on its own merits.", "source_ids": [ "nhlbi-apnea", "p-maki", "p-joffe" ] } ] }, { "id": "bone-muscle-and-loading", "role": "findings", "title": "How bone and strength fit into midlife care", "intro": "Feeling stronger, improving a density measurement and preventing a fracture are related but different outcomes.", "items": [ { "label": "Understand why bone health deserves attention during the transition", "text": "Bone is living tissue that is continually renewed. Cells remove old material and other cells replace it. The Menopause Society's osteoporosis statement explains that estrogen decline can accelerate removal beyond replacement around the transition, producing a period of faster bone loss. This can happen even when someone feels well. Bone strength depends on density and structure, while whether a fall becomes a fracture also depends on other factors. A density test, a medicine and an exercise session therefore address overlapping rather than identical parts of the problem. Hormone therapy can prevent bone loss in suitable users, but established osteoporosis needs its own management discussion. A person who is active may still need fracture-risk assessment; a person with low density may still benefit from suitably adapted activity.", "source_ids": [ "society-bone-2021", "society-bone-handout" ] }, { "label": "Use risk and age to guide the bone-screening conversation", "text": "Bone mineral density measures how much mineral is present in a defined area of bone. A DXA scan is a low-dose X-ray test commonly used to measure it. Lower density can help identify osteoporosis, a condition associated with greater fracture risk, but density alone does not describe every reason a person may break a bone. USPSTF's 2025 recommendation is to screen women 65 or older, and postmenopausal women under 65 who are at increased risk after a clinical risk assessment. Factors include low body weight, a parent's hip fracture, smoking and excess alcohol use. This recommendation is for screening; people with known osteoporosis or a fragility fracture need assessment and management rather than a first-screening rule. Ask whether the recommendation fits your history.", "source_ids": [ "uspstf-bone" ] }, { "label": "Read heavy-lifting evidence together with its supervision", "text": "Belinda Beck and colleagues' LIFTMOR trial studied 101 screened postmenopausal women with low bone mass for eight months. It compared a twice-weekly, thirty-minute supervised program of high-intensity resistance and impact training with lower-intensity home exercise. The research protocol included five sets of five repetitions above 85% of a one-repetition maximum, meaning the greatest weight a person could lift once. Spine density increased about 2.9% in the supervised group versus a 1.2% decline in controls, with better functional performance and one reported minor back spasm. These details are the study exposure, not your starting workout. The short trial measured density and function, not proof of fewer lifetime fractures. Screening, coaching and progression were part of the intervention; unsupervised heavy lifting is a different exposure.", "source_ids": [ "liftmor-2018", "p-beck" ] }, { "label": "Choose repeatable movement for its own health outcomes", "text": "WHO's adult activity guidance includes strengthening all major muscle groups on at least two days each week, alongside aerobic activity; some activity is better than none. That population guidance is a useful direction, not a personal prescription or a demand to meet a heavy-lifting protocol immediately. Walking supports activity, while bone-targeted loading and resistance exercise ask different things of the body. Kohrt's research explains why estrogen, exercise, metabolism and body composition all belong in the midlife picture. If you already train, discuss whether your load, technique or supervision fits your health. If you are starting or have low bone mass, a qualified clinician or exercise professional can help adapt the work. Sudden severe pain or an injury needs assessment rather than a heavier session.", "source_ids": [ "who-activity", "p-kohrt", "liftmor-2018" ] } ] }, { "id": "evaluate-treatment-claims", "role": "perspectives", "title": "How to judge competing treatment promises", "intro": "A disagreement in marketing is not automatically an unresolved scientific question. Ask what evidence would justify the specific promise.", "items": [ { "label": "Check the product evidence behind the word bioidentical", "text": "Bioidentical means that a molecule has the same chemical structure as a hormone made by the body. FDA-approved estradiol and micronized progesterone products can already meet that description. A compounded product is mixed to a prescription rather than approved as that finished formulation. The Endocrine Society says evidence does not establish that custom compounded hormone mixtures are safer or more effective, and warns about inconsistent dose and purity. The FDA's account of the National Academies review identifies weak clinical evidence and limited oversight as public-health concerns. This is a product-testing and quality question, not a contest between 'natural' and 'synthetic' words. A documented need for compounding, such as an ingredient allergy, is a clinician-pharmacy decision. The label alone does not justify replacing a regulated product.", "source_ids": [ "endo-compounding", "fda-nasem" ] }, { "label": "Ask what a saliva test has been shown to predict", "text": "A saliva hormone panel can look precise because it produces numbers and a customized-looking recipe. Precision of presentation is different from demonstrated clinical usefulness. The Endocrine Society explains that hormone levels vary with physiology and the way medicines are absorbed and processed, and that evidence does not validate saliva-based customization as a reliable dosing method. This is separate from a clinician ordering a test for a specific diagnostic question. Jen Gunter's public education helps readers recognize such gaps between a convincing story and tested medicine, but the supporting authority here is the professional statement. Bring symptoms, history and treatment goals to the prescriber. Ask what outcome the test-guided approach improves over ordinary care, and whether that comparison has actually been studied.", "source_ids": [ "endo-compounding", "p-gunter" ] }, { "label": "Keep exercise and comfort strategies tied to the result they can deliver", "text": "A fan, clothing changes, walking or yoga may make an episode or a day more manageable. The Menopause Society's 2023 evidence review did not recommend exercise, yoga, cooling or trigger-avoidance lists as proven vasomotor treatments. That is an outcome-specific conclusion, not a reason to abandon activity or something that improves your comfort. WHO's guidance still supports movement for health, and LIFTMOR tested loading for bone. Public advice becomes misleading when it turns those benefits into a guarantee that heat will stop. You can keep a helpful routine while seeking evidence-based symptom care if needed. Improvement in muscle or comfort does not establish a reduction in the frequency of hot flashes.", "source_ids": [ "society-nonhormone-2023", "who-activity", "society-hot-flashes" ] }, { "label": "Compare herbal promises with supported nonhormone choices", "text": "Black cohosh, soy extracts and mixed 'menopause support' products are often presented as gentler substitutes for treatment. The 2023 society review did not recommend supplements and herbal remedies for vasomotor symptoms because adequate, consistent benefit was not established. A soy food in an ordinary diet is a different question from using an extract as a hot-flash treatment. Supplements can have adverse effects and interactions; 'natural' does not answer those questions. Show a clinician or pharmacist the ingredients rather than assuming a blend's marketing name describes what it contains. If you prefer to avoid hormones, ask about the named nonhormone options with evidence. Heavy bleeding or severe sleep disruption deserves assessment while that choice is being considered.", "source_ids": [ "society-nonhormone-2023", "society-nonhormone-handout" ] } ] }, { "id": "check-common-claims", "role": "findings", "title": "Check the claim before acting on it", "intro": "These verdicts concern the statement as written. Read the matching explanation above for the finding and its limits.", "items": [ { "label": "Use the twelve-month marker with its exceptions", "text": "Claim: 'Menopause means periods have stopped for twelve months.' Verdict: established for natural menopause when another cause or hormonal treatment does not explain the absence. Surgery and younger age can require a different assessment. The marker names a stage retrospectively; it does not decide whether symptoms deserve care before or after that point.", "source_ids": [ "cms-stages" ] }, { "label": "Allow a longer course for frequent heat", "text": "Claim: 'Frequent hot flashes usually last only a year or two.' Verdict: not supported as written. SWAN's median was 7.4 years among women with frequent symptoms. Some courses are shorter, others much longer. A group estimate corrects the fixed timer but does not determine your last episode.", "source_ids": [ "avis-duration" ] }, { "label": "Make hormone therapy an individual choice", "text": "Claim: 'Every woman in menopause should take hormone therapy.' Verdict: not supported as written. Treatment depends on symptoms, indications, history, contraindications and preferences. Hormones are an effective option for heat and have bone effects; those benefits do not create a universal mandate or a general prescription for lifelong disease prevention.", "source_ids": [ "society-ht-handout", "whi-review-2024" ] }, { "label": "Keep the WHI conclusion attached to what it tested", "text": "Claim: 'The WHI proved that no one should ever take hormones.' Verdict: not supported as written. The trials raised important regimen-specific risks for prevention. Current interpretation still allows symptom treatment in suitable women near menopause. Neither discarding the trial nor turning it into a lifetime ban faithfully represents the evidence.", "source_ids": [ "whi-review-2024" ] }, { "label": "Separate activity benefits from a heat-treatment guarantee", "text": "Claim: 'Exercise is a proven treatment for hot flashes.' Verdict: not supported as written. The society review did not recommend exercise as vasomotor therapy. Muscle, function and bone remain worthwhile reasons for activity. Choosing it for those reasons does not require claiming that it will switch off heat.", "source_ids": [ "society-nonhormone-2023", "who-activity" ] }, { "label": "Require evidence for a custom-product safety promise", "text": "Claim: 'Custom compounded bioidentical hormones are safer than approved products.' Verdict: not supported as written. The National Academies assessment found inadequate rigorous evidence and quality-oversight concerns. Body-identical molecules also exist in approved products. A custom label or saliva-derived recipe does not establish a safety advantage.", "source_ids": [ "fda-nasem" ] }, { "label": "Recognize structured insomnia care as a tested option", "text": "Claim: 'CBT-I can improve insomnia during the menopause transition.' Verdict: established. McCurry's randomized trial found better insomnia outcomes than menopause education through 24 weeks in women with insomnia and hot flashes. This supports the possibility of benefit; it is not a guarantee or a substitute for investigating breathing pauses.", "source_ids": [ "mccurry-cbti" ] } ] }, { "id": "get-the-right-level-of-care", "role": "cautions", "title": "When to seek assessment promptly", "intro": "A diary helps an appointment. It should never postpone assessment of concerning symptoms.", "items": [ { "label": "Have new or unusual bleeding assessed", "text": "Bleeding or spotting after natural menopause should be reported even if it happens only once or is a small amount. NHS guidance explains that it is often not serious but can sometimes signal a condition needing treatment, including cancer. Very heavy or unusually frequent bleeding during the transition also deserves assessment; it should not automatically be attributed to hormone fluctuation. HRT adds another distinction: some regimens intentionally produce scheduled bleeding, and NICE's April 2026 guidance notes that unscheduled bleeding can occur early after starting or changing systemic HRT. Beyond the specified adjustment periods, prompt medical help is advised. Discuss any new, persistent or concerning bleeding with the prescriber rather than deciding for yourself that it is expected or waiting out a rule from this article.", "source_ids": [ "nhs-postmenopausal-bleeding", "nhs-heavy-bleeding", "nice-ng23" ] }, { "label": "Use emergency help for sudden severe symptoms", "text": "Chest pain, fainting, sudden breathlessness or one-sided weakness should not be dismissed as a hot flash or ordinary midlife change. NIH heart-attack guidance and CDC stroke guidance emphasize prompt emergency assessment for relevant warning symptoms; call local emergency services, including 911 in the United States, when they occur. Severe bleeding with collapse or marked weakness also needs urgent help. This distinction protects the usefulness of ordinary symptom tracking: gradual patterns can inform a scheduled visit, while sudden severe changes need immediate attention. A page cannot determine which diagnosis explains the event. Do not wait to finish a diary or see whether a supplement, hormone dose or workout changes it.", "source_ids": [ "nhlbi-heart", "cdc-stroke", "nhs-heavy-bleeding" ] }, { "label": "Use this reading to prepare for care", "text": "This is a reading companion, not a diagnosis, hormone prescription, or clinic visit. Persistent or bothersome heat, night sweats, broken sleep, early period stop, or worry about bone belong with a qualified clinician who can take a history and tailor care. After more than a year without a period, new bleeding or spotting needs prompt medical review. Periods that stop before 45, very heavy or closely stacked bleeding, and sudden severe symptoms also need a person, not a page. Do not start, stop, or change hormone therapy, other medicines, or a training plan from this text. Chest pain, fainting, one-sided weakness, or sudden breathlessness need emergency care. This page does not treat one body or promise an outcome.\n\nNamed sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.", "source_ids": [ "nice-ng23", "cms-stages", "nhs-postmenopausal-bleeding", "nhlbi-heart", "cdc-stroke" ] } ] }, { "id": "prepare-one-useful-visit", "role": "next_steps", "title": "Bring one clear question to your next visit", "intro": "Choose the problem that matters most, while mentioning the others that may affect the decision.", "items": [ { "label": "Bring four lines that tell the clinician what has changed", "text": "Write a brief account of your cycle pattern, daytime heat or night sweats, sleep and daytime function, and the issue you want help with first. Add current medicines and supplements, relevant surgery, and any fracture, clot, cancer, liver or cardiovascular history. This translates the clinical-history approach used by NICE into a practical visit aid; it is not a diagnostic checklist. You might bring, 'My cycles have changed, heat wakes me, and I want to understand sleep and treatment options.' Ask what else should be assessed and which treatment outcome would count as worthwhile improvement. You do not need to resolve the hormone debate before requesting a conversation.", "source_ids": [ "nice-ng23", "society-ht-handout", "p-faubion" ] }, { "label": "Try a short diary that records interference", "text": "For a few ordinary weeks, note bleeding dates, a rough heat count, night sweats and whether they interrupted activity or sleep. Use simple words rather than treating the diary as a research-grade instrument. The field distinguishes frequency from interference, so include what you could not do or how long returning to sleep took. Bring what you have even if recording is incomplete. This is a suggested communication aid drawn from the kinds of outcomes researchers measure, not a validated home test or a requirement to delay care. New postmenopausal bleeding, very heavy bleeding or sudden severe symptoms belong in the care pathways above.", "source_ids": [ "society-hot-flashes", "menos-trials", "nhs-postmenopausal-bleeding" ] }, { "label": "Try a specific question about sleep care", "text": "If insomnia is the main problem, ask where you can access CBT-I and whether a separate sleep assessment is indicated. Mention heat, gasping or breathing pauses, mood and medicines so the clinician can consider overlapping causes. McCurry's research supports structured care delivered by telephone in a defined group, rather than the idea that everyone must reach an in-person specialist before anything can help. Availability, cost and the suitability of a program still need checking locally. If heat improves but sleep does not, bring that result back; it helps clarify the next question. For how people talk about sleep hours, see STUDself at /self/. Its experience map does not replace clinical sleep assessment.", "source_ids": [ "mccurry-cbti", "nhlbi-apnea", "p-mccurry" ] }, { "label": "Try a specific question about bone and supervised activity", "text": "Ask whether bone screening is due for your age and risk, and which kind of strength or impact activity fits your current health. Say what you already do; suitable progression is more useful than copying a study's maximum load. The screening recommendation and lifting trial answer different questions, so requesting one conversation does not commit you to either a scan or a high-intensity program. Agree on what symptoms or changes would prompt reassessment. For lifting after 40, see STUDfit at /fit/ for the community discussion. Keep exercise as health work, symptom treatment as a reviewed choice, and follow-up as an ordinary part of care.", "source_ids": [ "uspstf-bone", "liftmor-2018", "who-activity" ] } ] } ], "related": [ "sleep", "fitness", "anxiety" ] }, "sources": [ { "id": "who-menopause", "title": "Menopause", "url": "https://www.who.int/news-room/fact-sheets/detail/menopause", "kind": "official", "accessed_at": "2026-10-01", "supports": "Explains ovarian follicular loss, the twelve-month definition of natural menopause, variable symptoms and perimenopause.", "limitations": "Public education rather than a diagnostic or treatment algorithm." }, { "id": "endo-menopause", "title": "Menopause — Endocrine Library", "url": "https://www.endocrine.org/patient-engagement/endocrine-library/menopause", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Explains fluctuating hormones, changing cycle patterns and the role of clinical history in assessing atypical symptoms. Nanette Santoro is among its named clinical editors.", "limitations": "Page last updated January 24, 2022. Used for basic explanation, not an up-to-date medicine list or its simplified causal claims about mood." }, { "id": "mayo-menopause", "title": "Menopause — Symptoms and causes", "url": "https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Gives an average U.S. menopause age of 51 and distinguishes hysterectomy with ovaries remaining from removal of the ovaries.", "limitations": "A public summary; individual variation and other possible causes still require clinical assessment." }, { "id": "straw-2012", "title": "Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging", "url": "https://integration.sart.org/globalassets/_asrm/practice-guidance/practice-guidelines/pdf/executive-summary-of-the-straw.pdf", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Defines the persistent seven-day cycle difference, sixty-day gap, late-transition duration and endpoint of perimenopause used in reproductive-aging staging.", "limitations": "Research and clinical staging consensus rather than home diagnosis; medication-masked bleeding and special populations need different assessment." }, { "id": "cms-stages", "title": "Definition and Stages", "url": "https://www.canadianmenopausesociety.org/professionals/menopause-hub/definition/", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Defines menopause retrospectively, distinguishes stage from symptoms, and explains when medical interventions or other causes complicate the definition.", "limitations": "Professional overview, not a personalized diagnostic test. Population definitions should not delay abnormal-bleeding care." }, { "id": "nice-ng23", "title": "Menopause: identification and management — Recommendations (NG23)", "url": "https://www.nice.org.uk/guidance/ng23/chapter/Recommendations", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Sections 1.3.1–1.3.6 address clinical identification and testing; sections 1.8.4–1.8.5 address bleeding after systemic HRT; section 1.9 covers treatment review. The April 2026 bleeding guidance distinguishes the first six months after starting HRT and the first three months after a dose or preparation change from bleeding beyond those intervals, when prompt help is advised.", "limitations": "UK clinical guidance, not U.S. prescribing instructions. Full guideline/evidence collection not read cover to cover. Expected bleeding does not mean all bleeding can be ignored." }, { "id": "poi-guideline", "title": "Evidence-based guideline: Premature Ovarian Insufficiency", "url": "https://www.asrm.org/practice-guidance/practice-committee-documents/evidence-based-guideline-premature-ovarian-insufficiency--2024/", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "International guidance on before-40 POI, early menopause 40–44, intermittent ovarian activity in nonsurgical POI, distinct health/fertility needs and HT through usual menopause age. Current page title marks 2025; literature search ended January 30, 2024.", "limitations": "Many POI-specific options have limited evidence; clinician assessment required. This article uses it to explain the condition and the need for individualized care." }, { "id": "avis-duration", "title": "Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition", "url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2110996", "kind": "study", "accessed_at": "2026-10-01", "supports": "Reports SWAN analysis of 1,449 frequent-symptom participants; 7.4-year median, 4.5 years after final period among 881; earlier onset and group duration differences.", "limitations": "Observational, self-reported symptoms on at least six of prior fourteen days; selected symptomatic population. Medians and group associations are not personal predictions or proof of causation." }, { "id": "society-hot-flashes", "title": "Hot Flashes", "url": "https://menopause.org/patient-education/menopause-topics/hot-flashes", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Explains hot-flash and night-sweat definition, variation and symptom-management questions.", "limitations": "Public education. Comfort suggestions are not upgraded to trial-proven vasomotor therapy." }, { "id": "menos-trials", "title": "CBT effective in treating menopause symptoms", "url": "https://www.kcl.ac.uk/archive/news/ioppn/records/2012/feb/cbt-menopause", "kind": "official", "accessed_at": "2026-10-01", "supports": "The investigators' institutional report describes MENOS1 (96 breast-cancer survivors) and MENOS2 (140 otherwise healthy women): improved problem ratings through 26 weeks.", "limitations": "An institutional trial report rather than a review of the complete journal methods; it does not support a guarantee of no side effects." }, { "id": "crandall-review", "title": "Management of Menopausal Symptoms: A Review", "url": "https://jamanetwork.com/journals/jama/article-abstract/2801054", "kind": "review", "accessed_at": "2026-10-01", "supports": "The 2023 review abstract reports 50%–75% VMS prevalence during transition; approximate 75% average frequency reduction with systemic estrogen; treatment and prevention distinction.", "limitations": "Abstract inspected, not paywalled full text; pooled estimates, not individual benefit or head-to-head ranking. The discussion here concerns vasomotor symptoms." }, { "id": "society-ht-2022", "title": "The 2022 hormone therapy position statement of The North American Menopause Society", "url": "https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Addresses routes, contraindications, bone benefits, age, timing and duration. It describes a generally favorable balance for suitable symptomatic women under 60 or within ten years of menopause onset, without contraindications.", "limitations": "2022 consensus, not a new trial or updated product label. Evidence varies by formulation and route; no large route-comparison outcome RCT claimed. Not all 28 pages read line by line." }, { "id": "society-ht-handout", "title": "Deciding About Hormone Therapy Use", "url": "https://menopause.org/wp-content/uploads/default-document-library/MenoNote-Deciding-About-HT-2025.pdf", "kind": "professional", "accessed_at": "2026-10-01", "supports": "A two-page society handout about symptom decisions, uterus/progestogen considerations and individualized review.", "limitations": "2025 educational handout, not a prescription or evidence of a universal duration rule." }, { "id": "society-ht-patient", "title": "Menopause Topics: Hormone Therapy", "url": "https://menopause.org/patient-education/menopause-topics/hormone-therapy", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Explains systemic treatment, endometrial protection when uterus present and possible route-related clot-risk difference.", "limitations": "Public simplifications and exact cancer-year claims are not reproduced as universal safety thresholds. Original trials and position statement govern nuanced comparison." }, { "id": "society-nonhormone-2023", "title": "The 2023 nonhormone therapy position statement of The North American Menopause Society", "url": "https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Sets out recommended interventions and evidence tiers; exercise/yoga/cooling/supplement conclusions are specific to vasomotor outcomes.", "limitations": "Predates December 2024 fezolinetant boxed warning and October 2025 elinzanetant approval. No DIY prescribing, combination plan or assumption that nonhormone means harmless." }, { "id": "society-nonhormone-handout", "title": "Nonhormone Treatments for Hot Flashes and Night Sweats", "url": "https://menopause.org/wp-content/uploads/default-document-library/nonhormone-treatment-menonote_f5afc19f-211e-4c1f-8a04-b2d558c6fa66.pdf", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Distinguishes supported nonhormone options from popular approaches.", "limitations": "Patient education; no guarantee, dosage plan or complete current-label review." }, { "id": "fda-veozah-safety", "title": "FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause", "url": "https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due", "kind": "official", "accessed_at": "2026-10-01", "supports": "The December 16, 2024 boxed-warning update specifies liver tests before treatment, monthly for the first three months, and at months six and nine, plus an urgent response to liver-injury symptoms.", "limitations": "Historical safety communication as hosted October 1, 2026; not represented as latest complete prescribing label. Current exact product instructions remain prescriber's responsibility." }, { "id": "fda-veozah-label", "title": "VEOZAH (fezolinetant) tablets — prescribing information, revised December 2024", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216578s004lbl.pdf", "kind": "official", "accessed_at": "2026-10-01", "supports": "Contains the boxed liver-injury warning and monitoring requirements described in the safety update.", "limitations": "Explicitly December 2024 label, not claimed to be newest complete label; no dose recommendations in article." }, { "id": "fda-lynkuet-snapshot", "title": "Drug Trials Snapshots: LYNKUET", "url": "https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-lynkuet", "kind": "official", "accessed_at": "2026-10-01", "supports": "Documents October 24, 2025 approval; OASIS efficacy participants and episode criteria; approximately 3.2 extra daily episodes reduced versus placebo at week twelve; age and subgroup limitations.", "limitations": "An original-approval snapshot rather than the latest label or a head-to-head treatment comparison. The age tables report a range of 40–65, while the summary gives a conflicting cutoff; this article uses the tabulated range. The snapshot's incorrect link to an unrelated drug label was excluded." }, { "id": "fda-lynkuet-label", "title": "LYNKUET (elinzanetant) capsules — prescribing information, revised October 2025", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219469s000lbl.pdf", "kind": "official", "accessed_at": "2026-10-01", "supports": "The original approval label describes NK1/NK3 mechanism, baseline and three-month liver assessment, daytime impairment, interactions and pregnancy contraindication.", "limitations": "Original approval label, not claimed newest complete label. No doses or self-management protocol proposed; current product assessment belongs to prescriber." }, { "id": "whi-2002", "title": "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial", "url": "https://jamanetwork.com/journals/jama/fullarticle/195120", "kind": "study", "accessed_at": "2026-10-01", "supports": "Reports 16,608 participants, ages 50–79, specific oral CEE/MPA doses, 5.2-year follow-up, stopped prevention trial, major harms/benefits and absolute breast-cancer excess.", "limitations": "One regimen and prevention population with mean age around 63; does not test every modern formulation or establish a universal ban. Selected relevant report sections inspected." }, { "id": "whi-followup-2013", "title": "Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials", "url": "https://jamanetwork.com/journals/jama/fullarticle/1745676", "kind": "study", "accessed_at": "2026-10-01", "supports": "Reviews thirteen years of findings from both randomized trials, including combined/estrogen-alone breast patterns and absolute-event differences by age.", "limitations": "Age subgroup interpretation and extended follow-up have limits; not a new randomized test of early modern therapy. Different regimens and uterine-status populations remain separate." }, { "id": "whi-review-2024", "title": "The Women's Health Initiative Randomized Trials and Clinical Practice: A Review", "url": "https://jamanetwork.com/journals/jama/article-abstract/2818206", "kind": "review", "accessed_at": "2026-10-01", "supports": "The review abstract concludes that WHI does not support HT for cardiovascular/other chronic-disease prevention; symptom care in suitable early-menopause women remains appropriate.", "limitations": "Abstract inspected, not entire paywalled review. Does not establish a preventive indication for all formulations or prescribe for visitors." }, { "id": "fda-ht-labels-2026", "title": "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products", "kind": "official", "accessed_at": "2026-10-01", "supports": "The February 12, 2026 announcement describes initial six products' approved boxed-warning changes and distinction from November 2025 request.", "limitations": "Regulatory announcement, not a new trial, a record of all subsequent product changes or proof of absent risk. Broader promotional prevention interpretations not adopted." }, { "id": "mccurry-cbti", "title": "Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial", "url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2522398", "kind": "study", "accessed_at": "2026-10-01", "supports": "Reports 106 participants, six telephone sessions, insomnia-score changes 9.9 versus 4.7 at eight weeks, sustained differences at 24 weeks, unchanged between-group flash frequency.", "limitations": "Single-site, selected largely White group; no apnea treatment, app equivalence, permanent cure or self-directed sleep-restriction plan claimed." }, { "id": "nhlbi-apnea", "title": "Sleep Apnea — Symptoms", "url": "https://www.nhlbi.nih.gov/health/sleep-apnea/symptoms", "kind": "official", "accessed_at": "2026-10-01", "supports": "Explains why breathing pauses/gasping/snoring, daytime symptoms and presentation in women justify a separate assessment.", "limitations": "Symptom education, not home diagnosis. Sleep-study and treatment instructions excluded." }, { "id": "society-bone-2021", "title": "Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society", "url": "https://menopause.org/wp-content/uploads/professional/2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Explains bone remodeling imbalance with estrogen decline; density versus strength/fracture; individualized management.", "limitations": "2021 North American consensus; no personal osteoporosis-treatment algorithm. Current screening age/risk recommendations sourced separately to USPSTF 2025." }, { "id": "society-bone-handout", "title": "Postmenopausal Osteoporosis — MenoNote", "url": "https://menopause.org/wp-content/uploads/professional/menonote-osteoporosis.pdf", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Explains bone risk and osteoporosis for patients.", "limitations": "Educational summary, not an individualized scan, drug or exercise decision." }, { "id": "uspstf-bone", "title": "Osteoporosis to Prevent Fractures: Screening", "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "The January 2025 recommendation addresses women 65+; younger postmenopausal women at increased risk following clinical assessment; DXA; risk factors and exclusions.", "limitations": "Population screening guidance excludes known osteoporosis/fragility-fracture cases. Does not prescribe treatment or give a personal FRAX threshold." }, { "id": "liftmor-2018", "title": "High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial", "url": "https://pubmed.ncbi.nlm.nih.gov/28975661/", "kind": "study", "accessed_at": "2026-10-01", "supports": "The primary abstract describes 101 screened participants in an eight-month supervised trial, including five sets of five repetitions above 85% of one-repetition maximum, changes in spine density and one minor back spasm.", "limitations": "This account relies on the abstract; full text was unavailable for review. The small, selected and supervised study does not establish a reduction in fractures or the safety of unsupervised lifting." }, { "id": "who-activity", "title": "Physical activity", "url": "https://www.who.int/news-room/fact-sheets/detail/physical-activity", "kind": "official", "accessed_at": "2026-10-01", "supports": "Describes adult aerobic and muscle-strengthening guidance, including work for major muscle groups on two or more days and the value of some activity over none.", "limitations": "Population recommendation, not a menopause-treatment trial or individual gym program; full guideline PDF not claimed read." }, { "id": "endo-compounding", "title": "Compounded Bioidentical Hormone Therapy", "url": "https://www.endocrine.org/advocacy/position-statements/compounded-bioidentical-hormone-therapy", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "The 2019 statement addresses molecule definition, approved body-identical products, lack of superiority evidence, variable quality and unsupported saliva customization.", "limitations": "Position statement, not a new outcomes trial. Does not deny documented clinical compounding needs or adjudicate every pharmacy." }, { "id": "fda-nasem", "title": "National Academies of Science, Engineering, and Medicine (NASEM) Study on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy", "url": "https://www.fda.gov/drugs/human-drug-compounding/national-academies-science-engineering-and-medicine-nasem-study-clinical-utility-treating-patients", "kind": "official", "accessed_at": "2026-10-01", "supports": "The FDA's summary of the independent July 2020 report describes lack of rigorous clinical safety/effectiveness evidence and limited oversight.", "limitations": "Official report summary, not complete 2020 book; absence of superiority evidence is not proof that every compounded preparation always causes harm." }, { "id": "nhs-postmenopausal-bleeding", "title": "Postmenopausal bleeding", "url": "https://www.nhs.uk/symptoms/post-menopausal-bleeding/", "kind": "official", "accessed_at": "2026-10-01", "supports": "The NHS page, reviewed September 24, 2026, explains assessment needed even for one small episode, common benign causes and potential cancer relevance.", "limitations": "UK public triage information; not a cancer diagnosis, a universal HRT-bleeding rule or a U.S. referral-time guarantee." }, { "id": "nhs-heavy-bleeding", "title": "Heavy periods", "url": "https://www.nhs.uk/conditions/heavy-periods/", "kind": "official", "accessed_at": "2026-10-01", "supports": "Explains symptoms and assessment of heavy periods and bleeding changes.", "limitations": "Public education; no home bleeding diagnosis or treatment algorithm. Urgent symptoms still require clinical assessment." }, { "id": "nhlbi-heart", "title": "Heart Attack — Symptoms", "url": "https://www.nhlbi.nih.gov/health/heart-attack/symptoms", "kind": "official", "accessed_at": "2026-10-01", "supports": "Explains warning symptoms and the need for prompt emergency help.", "limitations": "Does not mean every chest symptom is a heart attack; used for escalation, not diagnosis." }, { "id": "cdc-stroke", "title": "Signs and Symptoms of Stroke", "url": "https://www.cdc.gov/stroke/signs-symptoms/index.html", "kind": "official", "accessed_at": "2026-10-01", "supports": "The May 19, 2026 CDC guidance explains why sudden one-sided weakness and other stroke symptoms require immediate emergency help.", "limitations": "Used only for emergency escalation; no stroke risk score or differential diagnosis." }, { "id": "question-hrt-cbt", "title": "HRT guidance update UK — r/Menopause discussion", "url": "https://www.reddit.com/r/Menopause/comments/1glpjxt/hrt_guidance_update_uk/", "kind": "question_signal", "accessed_at": "2026-10-01", "supports": "Discussion illustrates confusion about whether talking therapy complements or replaces hormones, and why symptom frequency, interference and treatment choice need to be distinguished.", "limitations": "Qualitative self-selected discussion, including unsupported prevention claims; no comment is factual medical authority or representative prevalence evidence." }, { "id": "question-guidance-access", "title": "Hormone therapy recommendations — r/Menopause discussion", "url": "https://www.reddit.com/r/Menopause/comments/1dfctw9/hormone_therapy_recommendations_thought_folks/", "kind": "question_signal", "accessed_at": "2026-10-01", "supports": "Discussion illustrates how people use professional recommendations when seeking care, informing the article's appointment preparation.", "limitations": "A qualitative source of reader questions, not medical evidence; treatment claims rely on the professional sources cited separately." }, { "id": "p-faubion", "title": "Stephanie S. Faubion — official professional profile", "url": "https://www.mayoclinic.org/biographies/faubion-stephanie-s-m-d-m-b-a/bio-20054845", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, MBA; Mayo Clinic internist and director of its Center for Women's Health. Mayo's public biography includes an accessible explanation of midlife symptoms and clinical education. Research findings are supported by the studies and guidelines cited separately.", "limitations": "A clinical leader's public explanation is not a prescription or a trial of every regimen." }, { "id": "p-manson", "title": "JoAnn E. Manson — official professional profile", "url": "https://www.health.harvard.edu/authors/joann-manson-md-drph", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, DrPH; Harvard professor of medicine and Brigham and Women's Hospital chief of preventive medicine. Harvard public-health writing and WHI reviews translate the prevention findings into clinical questions. Research findings are supported by the studies and guidelines cited separately.", "limitations": "WHI regimens and populations do not represent every modern therapy; public education is not individualized care." }, { "id": "p-santoro", "title": "Nanette F. Santoro — official professional profile", "url": "https://medschool.cuanschutz.edu/ob-gyn/divisions/division-of-reproductive-sciences/our-faculty/nanette-santoro-md", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; E. Stewart Taylor Professor of Obstetrics and Gynecology, University of Colorado Anschutz. Public university research description and professional menopause education explain changing ovarian function. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Fluctuating physiology cannot date one reader's final period or turn one blood test into a verdict." }, { "id": "p-thurston", "title": "Rebecca C. Thurston — official professional profile", "url": "https://www.psychiatry.pitt.edu/about-us/our-people/rebecca-c-thurston-phd", "kind": "professional", "accessed_at": "2026-10-01", "supports": "PhD; Pittsburgh Foundation Chair in Women's Health and Dementia and Distinguished Professor of Psychiatry, University of Pittsburgh. Official research biography and selected publications explain vasomotor symptoms in relation to daily life and health. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Observational associations do not prove that treating flashes prevents cardiovascular disease." }, { "id": "p-joffe", "title": "Hadine Joffe — official professional profile", "url": "https://bidmc.org/departments-divisions/psychiatry/team", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, MSc; Chair and Chief of Psychiatry, Beth Israel Deaconess Medical Center. Public institutional role and authored menopause/sleep research bring mood, insomnia and heat into one assessable picture. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Current role is BIDMC; older Brigham/Connors affiliations in prior publications are historical. Research does not diagnose a reader." }, { "id": "p-maki", "title": "Pauline M. Maki — official professional profile", "url": "https://chicago.medicine.uic.edu/profiles/maki-pauline/", "kind": "professional", "accessed_at": "2026-10-01", "supports": "PhD; Professor of Psychiatry, Psychology and Obstetrics and Gynecology; Senior Director of Research, UIC Center for Research on Women and Gender. Official profile describes menopause, cognition and mood research and professional guideline contributions. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Cognitive complaints and depression need their own assessment; no dementia-prevention indication is inferred." }, { "id": "p-harlow", "title": "Siobán D. Harlow — official professional profile", "url": "https://sph.umich.edu/faculty-profiles/harlow-sioban.html", "kind": "professional", "accessed_at": "2026-10-01", "supports": "PhD; Professor Emerita of Epidemiology and Obstetrics and Gynecology, University of Michigan. Public research profile explains SWAN and the internationally used reproductive-aging staging system. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Research stages provide a common language rather than a personal diagnostic algorithm." }, { "id": "p-shufelt", "title": "Chrisandra L. Shufelt — official professional profile", "url": "https://www.mayo.edu/research/faculty/shufelt-chrisandra-l-m-d/bio-20542101", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, MS; Mayo Clinic women's-health and cardiovascular-hormone researcher. Official research description and society guidance make nonhormone options and vascular questions accessible. Research findings are supported by the studies and guidelines cited separately.", "limitations": "The 2023 recommendations predate later drug approvals and safety changes; route evidence has randomized-trial limits." }, { "id": "p-crandall", "title": "Carolyn J. Crandall — official professional profile", "url": "https://www.uclahealth.org/cancer/members/carolyn-crandall", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, MS; UCLA professor of medicine and internal-medicine physician. Official profile and JAMA clinical reviews explain treatment evidence without requiring a headline-level conclusion. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Review estimates are group results, not personal efficacy promises; breast findings stay attached to the regimen." }, { "id": "p-kohrt", "title": "Wendy M. Kohrt — official professional profile", "url": "https://medschool.cuanschutz.edu/center-for-womens-health-research/about-us/faculty-leadership/wendy-kohrt", "kind": "professional", "accessed_at": "2026-10-01", "supports": "PhD; Distinguished Professor in Geriatric Medicine and Nancy Anschutz Chair in Women's Health Research, University of Colorado Anschutz. University profile and public muscle-health education explain how exercise and estrogen affect midlife physiology. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Physiology research does not establish one gym prescription or make exercise a vasomotor treatment." }, { "id": "p-beck", "title": "Belinda R. Beck — official professional profile", "url": "https://www.griffith.edu.au/griffith-health/school-allied-health-sport-social-work/research/exercise-science-research", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Professor of bone and exercise research, Griffith University. Official exercise-science team page describes bone-health research and its translation into clinical services. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Small supervised trial is not proof of fracture prevention or safety of unsupervised lifting; clinical services are not themselves independent trials." }, { "id": "p-hunter", "title": "Myra S. Hunter — official professional profile", "url": "https://www.kcl.ac.uk/people/myra-hunter", "kind": "professional", "accessed_at": "2026-10-01", "supports": "PhD; Emeritus Professor of Clinical Health Psychology, King's College London. Public biography describes menopause-focused CBT trials, books and self-help manuals. Research findings are supported by the studies and guidelines cited separately.", "limitations": "CBT does not mean symptoms are imagined, nor does it replace assessment or every other treatment." }, { "id": "p-gunter", "title": "Jen Gunter — official professional profile", "url": "https://www.ted.com/speakers/jen_gunter", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; obstetrician-gynecologist and pain-medicine physician, as identified by TED. TED's official speaker biography and Body Stuff public education address menopause myths and treatment language. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Public communication is not primary trial evidence. The cited TED biography supports the role described here; a current Kaiser affiliation was not established." }, { "id": "p-christmas", "title": "Monica Christmas — official professional profile", "url": "https://www.uchicagomedicine.org/find-a-physician/physician/monica-christmas", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; University of Chicago obstetrician-gynecologist, director of its menopause program and Center for Women's Integrated Health. Official physician profile and public Q&A explain how symptom care differs across patients. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Her inclusion does not imply endorsement of this article or establish one treatment duration for all readers." }, { "id": "p-avis", "title": "Nancy E. Avis — official professional profile / primary research authorship", "url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2110996", "kind": "professional", "accessed_at": "2026-10-01", "supports": "PhD; SWAN investigator and lead author of the vasomotor-duration analysis. The primary report's accessible duration findings replace the common one- or two-year expectation. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Primary-paper role verified; current faculty appointment is not claimed. Cohort medians do not predict one person's course." }, { "id": "p-mccurry", "title": "Susan M. McCurry — official professional profile", "url": "https://nursing.uw.edu/person/4376497-susan-m-mccurry/", "kind": "professional", "accessed_at": "2026-10-01", "supports": "PhD; Research Professor Emeritus, University of Washington School of Nursing. Official profile describes clinical psychology and sleep research in older adults and people with coexisting conditions, including menopause. Research findings are supported by the studies and guidelines cited separately.", "limitations": "Selected clinical trial does not establish equivalence of an app, unsupervised sleep restriction or apnea treatment." } ], "professional_panel": [ { "name": "Stephanie S. Faubion", "credential": "MD, MBA; Mayo Clinic internist and director of its Center for Women's Health", "official_url": "https://www.mayoclinic.org/biographies/faubion-stephanie-s-m-d-m-b-a/bio-20054845", "public_usefulness": "Mayo's public biography includes an accessible explanation of midlife symptoms and clinical education.", "contribution": "Chaired the 2022 hormone-therapy advisory panel; helps distinguish symptom treatment from a mandate.", "boundary": "A clinical leader's public explanation is not a prescription or a trial of every regimen.", "reviewed_at": "2026-10-01" }, { "name": "JoAnn E. Manson", "credential": "MD, DrPH; Harvard professor of medicine and Brigham and Women's Hospital chief of preventive medicine", "official_url": "https://www.health.harvard.edu/authors/joann-manson-md-drph", "public_usefulness": "Harvard public-health writing and WHI reviews translate the prevention findings into clinical questions.", "contribution": "WHI intervention and follow-up work makes regimen, age and absolute risk visible.", "boundary": "WHI regimens and populations do not represent every modern therapy; public education is not individualized care.", "reviewed_at": "2026-10-01" }, { "name": "Nanette F. Santoro", "credential": "MD; E. Stewart Taylor Professor of Obstetrics and Gynecology, University of Colorado Anschutz", "official_url": "https://medschool.cuanschutz.edu/ob-gyn/divisions/division-of-reproductive-sciences/our-faculty/nanette-santoro-md", "public_usefulness": "Public university research description and professional menopause education explain changing ovarian function.", "contribution": "Reproductive-aging and hormone-pattern research informs the clinical story behind cycle variation.", "boundary": "Fluctuating physiology cannot date one reader's final period or turn one blood test into a verdict.", "reviewed_at": "2026-10-01" }, { "name": "Rebecca C. Thurston", "credential": "PhD; Pittsburgh Foundation Chair in Women's Health and Dementia and Distinguished Professor of Psychiatry, University of Pittsburgh", "official_url": "https://www.psychiatry.pitt.edu/about-us/our-people/rebecca-c-thurston-phd", "public_usefulness": "Official research biography and selected publications explain vasomotor symptoms in relation to daily life and health.", "contribution": "Studies physiological hot flashes, sleep and cardiovascular-health relationships.", "boundary": "Observational associations do not prove that treating flashes prevents cardiovascular disease.", "reviewed_at": "2026-10-01" }, { "name": "Hadine Joffe", "credential": "MD, MSc; Chair and Chief of Psychiatry, Beth Israel Deaconess Medical Center", "official_url": "https://bidmc.org/departments-divisions/psychiatry/team", "public_usefulness": "Public institutional role and authored menopause/sleep research bring mood, insomnia and heat into one assessable picture.", "contribution": "Coauthor of the MsFLASH insomnia trial; helps separate overlapping causes of a disrupted night.", "boundary": "Current role is BIDMC; older Brigham/Connors affiliations in prior publications are historical. Research does not diagnose a reader.", "reviewed_at": "2026-10-01" }, { "name": "Pauline M. Maki", "credential": "PhD; Professor of Psychiatry, Psychology and Obstetrics and Gynecology; Senior Director of Research, UIC Center for Research on Women and Gender", "official_url": "https://chicago.medicine.uic.edu/profiles/maki-pauline/", "public_usefulness": "Official profile describes menopause, cognition and mood research and professional guideline contributions.", "contribution": "Makes mood and cognitive complaints part of a clinical assessment rather than an automatic hormone explanation.", "boundary": "Cognitive complaints and depression need their own assessment; no dementia-prevention indication is inferred.", "reviewed_at": "2026-10-01" }, { "name": "Siobán D. Harlow", "credential": "PhD; Professor Emerita of Epidemiology and Obstetrics and Gynecology, University of Michigan", "official_url": "https://sph.umich.edu/faculty-profiles/harlow-sioban.html", "public_usefulness": "Public research profile explains SWAN and the internationally used reproductive-aging staging system.", "contribution": "Led STRAW+10 staging, including the seven-day and sixty-day cycle criteria.", "boundary": "Research stages provide a common language rather than a personal diagnostic algorithm.", "reviewed_at": "2026-10-01" }, { "name": "Chrisandra L. Shufelt", "credential": "MD, MS; Mayo Clinic women's-health and cardiovascular-hormone researcher", "official_url": "https://www.mayo.edu/research/faculty/shufelt-chrisandra-l-m-d/bio-20542101", "public_usefulness": "Official research description and society guidance make nonhormone options and vascular questions accessible.", "contribution": "Led the 2023 nonhormone statement; studies cardiovascular effects of hormonal environments.", "boundary": "The 2023 recommendations predate later drug approvals and safety changes; route evidence has randomized-trial limits.", "reviewed_at": "2026-10-01" }, { "name": "Carolyn J. Crandall", "credential": "MD, MS; UCLA professor of medicine and internal-medicine physician", "official_url": "https://www.uclahealth.org/cancer/members/carolyn-crandall", "public_usefulness": "Official profile and JAMA clinical reviews explain treatment evidence without requiring a headline-level conclusion.", "contribution": "Synthesizes vasomotor treatments and investigates bone and breast outcomes in WHI.", "boundary": "Review estimates are group results, not personal efficacy promises; breast findings stay attached to the regimen.", "reviewed_at": "2026-10-01" }, { "name": "Wendy M. Kohrt", "credential": "PhD; Distinguished Professor in Geriatric Medicine and Nancy Anschutz Chair in Women's Health Research, University of Colorado Anschutz", "official_url": "https://medschool.cuanschutz.edu/center-for-womens-health-research/about-us/faculty-leadership/wendy-kohrt", "public_usefulness": "University profile and public muscle-health education explain how exercise and estrogen affect midlife physiology.", "contribution": "Studies estrogen, activity, body composition and bone; supports separating strength goals from hot-flash relief.", "boundary": "Physiology research does not establish one gym prescription or make exercise a vasomotor treatment.", "reviewed_at": "2026-10-01" }, { "name": "Belinda R. Beck", "credential": "Professor of bone and exercise research, Griffith University", "official_url": "https://www.griffith.edu.au/griffith-health/school-allied-health-sport-social-work/research/exercise-science-research", "public_usefulness": "Official exercise-science team page describes bone-health research and its translation into clinical services.", "contribution": "LIFTMOR investigator who tested screened, supervised heavy loading for low bone mass.", "boundary": "Small supervised trial is not proof of fracture prevention or safety of unsupervised lifting; clinical services are not themselves independent trials.", "reviewed_at": "2026-10-01" }, { "name": "Myra S. Hunter", "credential": "PhD; Emeritus Professor of Clinical Health Psychology, King's College London", "official_url": "https://www.kcl.ac.uk/people/myra-hunter", "public_usefulness": "Public biography describes menopause-focused CBT trials, books and self-help manuals.", "contribution": "MENOS trials show how CBT can reduce the problem rating of heat even when episode frequency is a different outcome.", "boundary": "CBT does not mean symptoms are imagined, nor does it replace assessment or every other treatment.", "reviewed_at": "2026-10-01" }, { "name": "Jen Gunter", "credential": "MD; obstetrician-gynecologist and pain-medicine physician, as identified by TED", "official_url": "https://www.ted.com/speakers/jen_gunter", "public_usefulness": "TED's official speaker biography and Body Stuff public education address menopause myths and treatment language.", "contribution": "Public communication helps distinguish 'bioidentical' molecules from marketing claims about compounded products.", "boundary": "Public communication is not primary trial evidence. The cited TED biography supports the role described here; a current Kaiser affiliation was not established.", "reviewed_at": "2026-10-01" }, { "name": "Monica Christmas", "credential": "MD; University of Chicago obstetrician-gynecologist, director of its menopause program and Center for Women's Integrated Health", "official_url": "https://www.uchicagomedicine.org/find-a-physician/physician/monica-christmas", "public_usefulness": "Official physician profile and public Q&A explain how symptom care differs across patients.", "contribution": "Patient-centered menopause education supports reviewing purpose, benefit and risks over time.", "boundary": "Her inclusion does not imply endorsement of this article or establish one treatment duration for all readers.", "reviewed_at": "2026-10-01" }, { "name": "Nancy E. Avis", "credential": "PhD; SWAN investigator and lead author of the vasomotor-duration analysis", "official_url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2110996", "public_usefulness": "The primary report's accessible duration findings replace the common one- or two-year expectation.", "contribution": "SWAN longitudinal analysis of frequent vasomotor symptoms reports median duration and variation by timing and group.", "boundary": "Primary-paper role verified; current faculty appointment is not claimed. Cohort medians do not predict one person's course.", "reviewed_at": "2026-10-01" }, { "name": "Susan M. McCurry", "credential": "PhD; Research Professor Emeritus, University of Washington School of Nursing", "official_url": "https://nursing.uw.edu/person/4376497-susan-m-mccurry/", "public_usefulness": "Official profile describes clinical psychology and sleep research in older adults and people with coexisting conditions, including menopause.", "contribution": "Led the MsFLASH telephone-CBT-I trial showing sustained insomnia improvement without lower between-group flash frequency.", "boundary": "Selected clinical trial does not establish equivalence of an app, unsupervised sleep restriction or apnea treatment.", "reviewed_at": "2026-10-01" } ] }